gene editing

Affinia Therapeutics is a gene therapy company developing adeno-associated virus (AAV) gene therapies for rare and prevalent diseases, starting with diseases of the heart and nervous system. Its proprietary ART (Affinia Rationally-designed Therapies) platform uses AI and structural modeling to rationally design novel AAV capsids and therapeutic payloads. Its first program, AFTX-201, targets BAG3-associated dilated cardiomyopathy (DCM).

AAV-gene therapyAI and structural modelingcapsid engineeringgene replacementgene therapy manufacturingknockdownpayload designvectorized antibody

ASAKE Biotechnology, LLC is a privately held company based in Athens, Ohio, founded in 2020, that researches and develops novel health therapeutics utilizing natural resources. It specializes in biosynthetic technology and synthetic chemistry as well as emerging technologies including Proteolysis Targeting Chimeras (PROTAC), with research centered on infectious diseases, diabetes, and cancer.

bioanalytical chemistrybiosynthetic technologydrug design and synthesisProteolysis Targeting Chimeras (PROTAC)synthetic chemistry

Avalo is an agriculture technology company that uses a nature-based, AI-powered Rapid Evolution platform to develop more resilient, sustainable and profitable crops. Its approach combines naturally high genetic diversity, scalable predictive modeling, and Whole Genome AI (Interpretable Machine Learning) to unlock useful plant traits faster and more affordably than conventional breeding. Avalo works on crops including broccoli, sugarcane, tomato, cotton, rubber and rice, and partners with breeders, farmers, mills, producers and chefs.

AI-powered plant breedinggenomic analysisindustrial breedinginterpretable machine learningpredictive modeling

Biocytogen is a global provider of animal and cell model generation for preclinical research, offering gene-edited and humanized mouse models, cell lines, and integrated drug discovery services. Through its BioMice brand it supplies off-the-shelf and custom animal models, and it develops fully human antibody discovery platforms including the RenMice family (RenMab, RenLite, RenNano, RenTCRmimic, RenMice KO) based on its SUPCE gene-editing technology.

antibody discoverycolony management and breedingcryopreservationhumanized mouse modelsin vitro pharmacologyin vivo pharmacologyknockout/knockin mouse model generationnon-GLP toxicity studiesPK/PD studiesrederivation

Cquesta is an agricultural biotechnology company spun out of the Salk Institute's Harnessing Plants Initiative, holding exclusive rights to its patent-protected root gene portfolio. It improves root system architecture (RSA) of major crops to increase farmer profitability, stress resilience, and soil carbon storage for gigaton-scale CO₂ removal. The company develops commercial-ready seed traits through gene editing, transformation, genotyping, phenotyping, seed production, and field trialing, and licenses traits to seed and ag biotech companies.

field trialinggenotypingphenotypingroot system architecture improvementseed productiontransformation

GeneLancet Biosciences in Doylestown, Pennsylvania, is a precise gene editing company developing therapeutic cures for diseases with significant unmet needs using LgRNA-guided gene editing. It has developed proprietary LgRNA technology enabling scalable precise gene editing with ultra-pure, high quality ligated single molecule guide RNAs (LgRNA), and is developing LgRNA-conjugate-directed CRISPR polymerase editing (STAR) as therapeutics for neurodegenerative disorders (ALS and Alzheimer's disease) and cancers.

CRISPR polymerase editing (STAR)LgRNA production

InvivoSciences, Inc. (IVS) is a precision medicine company personalizing the drug development process using patient-derived and gene-edited human samples, including an automated, scalable, functional 3D engineered micro-human heart tissue platform. It integrates cell and tissue handling automation, tissue phenotyping assays, computational biology (AI), and human organ/tissue data to identify safety and efficacy profiles of treatments. Founded in 2001 in St. Louis, Missouri, with technology licensed from Washington University, and moved to Wisconsin in 20

3D engineered micro-human heart tissueautomated cell and tissue handlingbiomechanical assayscardiac toxicity assessmentscompound screeningcomputational biology/AIhigh-throughput phenotypinginduced pluripotent stem cell (iPSC) technologyoptical devices